Viking Therapeutics, Inc.
METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS

Last updated:

Abstract:

The present disclosure is directed to methods of administration of thyroid hormone receptor agonists. The disclosure provides methods wherein the activity of the given thyroid receptor agonists in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related disorders is maintained, while thyroid-related and thyroid axis-related side effects are reduced or eliminated.

Status:
Application
Type:

Utility

Filling date:

13 Sep 2017

Issue date:

22 Aug 2019